The most promising therapeutic strategy for HD aims to reduce mutant Htt expression, while sparing unmutated Htt. The transcription elongation complex Spt4/Spt5 is specifically required for mutant Htt transcription. Here, SUPT4H1 is linked to Huntington disease.